IgG anticardiolipin antibody titer > 40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study.
about
Treatment and monitoring of patients with antiphospholipid antibodies and thrombotic history (Hughes syndrome)Real world experience with antiphospholipid antibody tests: how stable are results over time?Evaluation of cardiac abnormalities and embolic sources in primary antiphospholipid syndrome by transesophageal echocardiography.Outcomes of patients with antiphospholipid syndrome after pulmonary endarterectomy.Autoantibodies to modified LDLs and other phospholipid-protein complexes as markers of cardiovascular diseases.Risk factors for arterial ischemic stroke in children.Neurologic manifestations of the antiphospholipid syndrome.Anticardiolipin antibody in vascular parkinsonism.Antiphospholipid syndrome: an overview.Stroke and the antiphospholipid syndrome: consensus meeting Taormina 2002.Antiphospholipid antibodies and stroke.What is antiphospholipid syndrome?The presence of multiple prothrombotic risk factors is associated with a higher risk of thrombosis in individuals with anticardiolipin antibodies.Laboratory diagnosis and management challenges in the antiphospholipid syndrome.Diagnosis of antiphospholipid syndrome.D-dimer level and the risk for thrombosis in systemic lupus erythematosus.A patient with bipolar disorder and antiphospholipid syndrome.Antiphospholipid syndrome and vascular ischemic (occlusive) diseases: an overview.Auto-antibodies as emergent prognostic markers and possible mediators of ischemic cardiovascular diseases.International consensus guidelines on anticardiolipin and anti-β2-glycoprotein I testing: report from the 13th International Congress on Antiphospholipid Antibodies.The management of stroke in antiphospholipid syndrome.Transient ischemic attack and stroke in systemic lupus erythematosus.The emerging role of multiple antiphospholipid antibodies positivity in patients with antiphospholipid syndrome.The antiphospholipid syndrome: from pathophysiology to treatment.Heterogeneity of autoantibodies against cardiolipin and oxidatively modified LDLs revealed by human monoclonal antibodies.Brain injury and cerebrovascular fibrin deposition correlate with reduced antithrombotic brain capillary functions in a hypertensive stroke model.Subsequent Thrombotic Outcomes in Patients with Ischemic Stroke with Antiphospholipid Antibody PositivityDo antiphospholipid antibodies increase the long-term risk of thrombotic complications in young patients with a recent TIA or ischemic stroke?Antiphospholipid antibodies correlate with stroke severity and outcome in patients with antiphospholipid syndrome.Alterations of cerebral blood flow and antiphospholipid antibodies in patients with systemic lupus erythematosus.Performance Evaluation and Clinical Associations of Immunoassays That Detect Antibodies to Negatively Charged Phospholipids Other Than Cardiolipin.Antiphospholipid Antibody Syndrome.A new Eu(3+)-labeled method for anticardiolipin antibody IgM.Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies.Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus
P2860
Q28193706-0889B716-013A-43B3-91C1-63F2446B1F34Q28218139-18124699-DB4C-4D87-8D9B-66E51DAF8F0CQ33334045-CF10E38B-6AD6-449C-8458-4DA41D210A75Q33412248-83C43A8E-B57A-4A20-B5EF-24A718C8C9D3Q33890407-11138B94-A860-4C9E-A555-A6D64ABA912CQ33929522-750FE3E7-1BF7-4462-A8B6-646DFFAA40D0Q34317751-88DEE6BE-C2AD-44E1-817A-DD10F219C33DQ34932954-ADB2CFCF-0389-405B-8EE8-418854E579CEQ35099505-AEC524E8-B32F-4700-B506-735FDCFCAC9AQ35189292-2197AB00-697C-4D0F-A60C-F2CE3A11725DQ35647424-402ABB98-853D-4646-923F-8CCA6CCF644CQ35940089-44605EEA-EC13-4F1B-B7F2-828037892496Q36229639-EDB10637-9AC4-4800-B605-7C4A86A6BE2AQ36458164-7C5BEEBA-9672-4858-9536-441A40DE1867Q36577371-ECE1432F-31B1-4258-A5DA-461BE29FC87EQ36947358-1DF39C8E-8E9E-4122-B5BC-5C2EB9A4074DQ36959771-B41174C1-F20C-44D4-B6A9-8D11C903F49BQ37045158-32587EF0-59F9-405C-AEE5-D20D1645EE34Q37824302-A091DBDF-27CD-4CBA-9487-43EF70F7A9F7Q37939730-EA62D04E-C64E-4367-9265-9C905D2EB7FEQ37959884-D5133D5A-1CAE-419C-85AA-D36D0EE2C92CQ38149851-E2525BBA-579B-4BC4-9EF8-BB1620A909B4Q38570944-0DA6056B-F427-4440-9365-05DF02D264ECQ38873953-89DFC7F3-EB63-4010-9C1C-CC71415B98D1Q40887411-F3FEF74F-ED96-435D-BAEE-47981E1F8260Q41747276-01D177AB-A3F8-49E3-BEE3-526D639EEF4EQ42646992-87D80725-C5F2-4243-900C-5FC9F7997B0DQ43717978-8D2C3081-E2A9-41B5-9A33-EDCB1E10A7BDQ48443751-58640CF6-C1AC-4095-97ED-4F15B74D4065Q48466057-5EFC3F40-9321-497A-B93A-55C50B478922Q52652019-7462BA30-10FC-461C-8EE7-93AA8E39644CQ53330685-BF127F74-6AB6-4848-AE33-D38AADFB7C34Q53591884-19373CFC-5982-49F2-B8AB-8776772DD700Q55547645-DAC92F4D-C9A6-458E-BF5C-C08582D71118Q57216969-18B9D28D-FC0D-4636-A2C9-72AFC59ACB51
P2860
IgG anticardiolipin antibody titer > 40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh-hant
name
IgG anticardiolipin antibody t ...... h. A prospective cohort study.
@en
IgG anticardiolipin antibody t ...... h. A prospective cohort study.
@nl
type
label
IgG anticardiolipin antibody t ...... h. A prospective cohort study.
@en
IgG anticardiolipin antibody t ...... h. A prospective cohort study.
@nl
prefLabel
IgG anticardiolipin antibody t ...... h. A prospective cohort study.
@en
IgG anticardiolipin antibody t ...... h. A prospective cohort study.
@nl
P2093
P356
P1433
P1476
IgG anticardiolipin antibody t ...... h. A prospective cohort study.
@en
P2093
H J Spencer
H J Winkler
K L Sawaya
L Salowich-Palm
S R Levine
P304
P356
10.1161/01.STR.28.9.1660
P407
P577
1997-09-01T00:00:00Z